News & Events about Cytokinetics Inc.
Cytokinetics (NASDAQ:CYTK Get Rating) had its price objective raised by stock analysts at The Goldman Sachs Group from $47.00 to $56.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical companys stock. The Goldman Sachs Groups ...
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug ...
Analysis from FORTITUDE-ALS Shows Predicted Survival Risk ScoreStrongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will Enrich forthe Enrollment of Faster Progressors SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, ...
Ticker Report
2 months ago
StockNews.com lowered shares of Cytokinetics (NASDAQ:CYTK Get Rating) from a hold rating to a sell rating in a research note released on Friday. Other equities analysts have also recently issued reports about the stock. Raymond James boosted their price objective on shares of Cytokinetics ...